|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||1.40 / 4.20|
Conatus Pharmaceuticals' (CNAT) patented liver drug emricasan has been identified as a promising treatment for the Zika virus.
Company's non-invasive BreathID® System to be used to quantitate liver function in Conatus Phase IIb clinical trial of emricasan; Currently no approved non-invasive diagnostic tests exist to diagnose or monitor NASH which affects 2-5% of the US population
Conference Call and Webcast Presentation at 8:00 a.m. ET Today
Late Breaker Oral Presentation Tomorrow to Detail Phase 2 Liver Cirrhosis Trial 3-month Results
Focusing on Initial Registration in NASH Cirrhosis With Parallel Development in NASH Fibrosis
Adding Long-term Safety Data to Support Initial Registration of Emricasan in Cirrhosis
Conatus Pharmaceuticals (CNAT) stock is increasing in mid-morning trading on Wednesday after the company said a Phase 2 trial of its liver drug showed positive results.